ライフサイエンスコーパス: body surface

1 those neurons and be transported back to the body surface.

2 ght that is scattered and reflected from the body surface.

3 uity for pain across multiple regions of the body surface.

4 tion of OBAP1 with other proteins in the oil body surface.

5 competing inputs were segregated on the cell body surface.

6 C nociceptors, that cover almost the entire body surface.

7 om a complex formation history of the parent body surface.

8 ctivity that may shape the microbiome on the body surface.

9 the distributed sensor network placed on the body surface.

10 pheral thermosensory neurons innervating the body surface.

11 tion of long-lived adaptive immune memory at body surfaces.

12 function of removing foreign materials from body surfaces.

13 play key roles in immunity and tolerance at body surfaces.

14 ls may be revealed by reflections from their body surface [4-7].

15 irectly detecting current shear across their body surface [5] or indirectly assessing drift direction

16 ection of microorganisms inhabiting the host body surface and cavities, shapes a micro-environment fo

17 sarcoidosis and may capture a wide range of body surface and cutaneous morphologic types.

18 Body surface and epicardial potentials were recorded sim

19 ral regions that help them to move about the body surface and feed on skin and gill debris.

20 tently after acute ischemia induction in all body-surface and intracardiac leads (P<0.0001).

21 area correlated significantly with age, sex, body surface, and endurance training.

22 tacles, locations of objects approaching the body surface are usually detected via the visual system

23 Body surfaces are colonized by resident microbes that ar

24 Patients with LVH (LVM/body surface area >/=116 and >/=96 g/m(2) in men and wom

25 hysician's Global Assessment score >/=3 with body surface area >10%).

26 hysician's Global Assessment score </=3 with body surface area </=10%) or severe (worst Physician's G

27 1 +/- 5.10 g [p = 0.012]) and LVM indexed to body surface area (-1.32 +/- 2.84 g/m(2) vs. placebo gro

28 ociated with weight (0.02 mm/kg; P=0.01) and body surface area (1.1 mm/m(2); P<0.001).

29 ence in age (65+/-10 versus 59+/-13; P=0.5), body surface area (2.0+/-0.2 versus 2.0+/-0.2 m(2); P=0.

30 29%]) or based on body weight (10 [48%]) and body surface area (4 [19%]).

31 atients with aortic valve area normalized to body surface area (AVA/BSA) <0.6 cm(2)/m(2); yet, this c

32 On the basis of AVA-indexed-to-body surface area (AVAi) and MG, patients were categoriz

33 effective diameters at each level to patient body surface area (BSA) and sex.

34 scores for common measurements adjusted for body surface area (BSA) and stratified by age, sex, race

35 ss index (BMI; weight (kg)/height (m)2), and body surface area (BSA) at ages 7-13 years and birth wei

36 values for FAC, TAPSE, and TAPSE indexed to body surface area (BSA) decreased over time (P=0.03 for

37 Recorded variables included maximal body surface area (BSA) detachment, SCORTEN (Score of To

38 Body surface area (BSA) of vitiligo lesions.RESULTS Pati

39 According to donor/recipient body surface area (BSA) ratio, patients were stratified

40 Body surface area (BSA) scaling has been used for prescr

41 xtensive cutaneous disease involving >90% of body surface area (BSA) suffered from severe symptoms re

42 nalysis, log-creatinine, sex, age, race, and body surface area (BSA) were significantly associated wi

43 xceptionally severe psoriasis at entry (>42% body surface area (BSA)) had a significantly increased r

44 2,044 participants had mild psoriasis (</=2% body surface area (BSA)), 1,377 had moderate psoriasis (

45 ncer was higher for participants with a high body surface area (BSA), great height, or excess weight

46 Body surface area (BSA)-adjusted chronic kidney disease

47 sage of the radiopharmaceutical according to body surface area (BSA).

48 Cardiac output was indexed to body surface area (cardiac index [CI]) for all analyses.

49 zation, and echocardiography) and indexed to body surface area (cardiac index [CI]).

50 0 +/- 6.3 to 75.5 +/- 6.3 mL.min(-1) . m(-2) body surface area (P < 0.01), because of improvements in

51 After adjusting for age (P = .090), body surface area (P = .073), and sex (P = .005), pulmon

52 f prior Puestow procedure (P = 0.018), lower body surface area (P = 0.048), higher islet equivalents

53 y with age (r=0.848), body length (r=0.871), body surface area (r=0.856), and body weight (r=0.825) a

54 LVEF of >/=50% but stroke volume indexed to body surface area (SVi) of </=35 ml m(-2); and 629 (54%)

55 lly injured, as demonstrated by mean % total body surface area (TBSA) (41.2 +/- 18.3 for adults and 5

56 included in the analysis, with a mean total body surface area (TBSA) burn of 7.2% and a mean age of

57 ll transfusion strategy in 20% or more total body surface area (TBSA) burn patients.

58 ned adult patients with burns over 20% total body surface area (TBSA) burn were prospectively randomi

59 ty, even after adjusting for age and % total body surface area (TBSA) burn.

60 jects is 42.5 +/- 16.0 years, the mean total body surface area (TBSA) burned is 18.5 +/- 16.4%, and t

61 ts with burns of at least 30% of their total body surface area (TBSA).

62 llitus (1.45 [1.39-1.51]), obesity in women (body surface area 2.2 versus 1.8: 1.44 [1.35-1.53]), fem

63 than those with hypertension (LA volume max/ body surface area 30.2+/-6.6 versus 33.0+/-9.0 mL/m(2);

64 stage II (end-diastolic volume [milliliters]/body surface area [BSA](1.3), end-systolic volume [milli

65 aluated whether the effect of clinical (age, body surface area [BSA], chronic kidney disease [CKD], a

66 easurements were corrected for age, sex, and body surface area according to reference data and progno

67 reased in a stepwise fashion with increasing body surface area affected by PsO (P for trend <0.001).

68 8-32 years]) were all male with an estimated body surface area affected with RDEB of 4% to 30%.

69 evere psoriasis defined by 3% or more of the body surface area affected.

70 ace area before vs. 58.9 +/- 17.5 mL/min per body surface area after therapy; P = 0.22); however, 3 p

71 apy using verteporfin at a dose of 6 mg/m(2) body surface area and 689 nm diode laser at an intensity

72 lied with verteporfin at a dose of 6 mg/m(2) body surface area and a 689 nm diode laser for 83 second

73 Great vessel areas correlated well with body surface area and age in controls and reference Z-sc

74 unilateral pectoralis muscle mass indexed to body surface area and attenuation (approximated by mean

75 mited disease to involvement of 30% of their body surface area and had evidence of pulmonary sarcoido

76 th burns covering more than 20% of the total body surface area and required at least one surgical int

77 es in end-diastolic volume indexed (EDVi) to body surface area and the ejection fraction (EF).

78 eters corresponding to pesticide deposition, body surface area and weight, surface-to-body transfer e

79 , days in intensive care unit, sex, age, and body surface area at evaluation.

80 in the Psoriasis Area and Severity Index and body surface area at the end of treatment.

81 ity alleles presented a greater reduction in body surface area at the intermediate point, which remai

82 e or after therapy (64.2 +/- 16.5 mL/min per body surface area before vs. 58.9 +/- 17.5 mL/min per bo

83 0 [95% CI, 2.2-22.8]; p < 0.001), a detached body surface area between 10% and 29% (odds ratio, 3.7 [

84 hours after injury, and more than 20% total body surface area burn requiring at least 1 surgical int

85 12 male pediatric burn patients (>30% total body surface area burn) and 12 young, healthy male subje

86 ed the varying effects of patient age, total body surface area burn, and inhalation injury on the pro

87 owed that a burn size of more than 60% total body surface area burned (an increase from 40% a decade

88 urn care setting, adults with over 40% total body surface area burned and children with over 60% tota

89 area burned and children with over 60% total body surface area burned are at high risk for morbidity

90 of 612 burned children [52% +/- 1% of total body surface area burned, ages 0.5-14 years (boys); ages

91 ome after controlling for age, gender, total body surface area burned, and inhalation injury (hazard

92 Age, total body surface area burned, and inhalation injury were als

93 +/- 15 years old and with 38% +/- 14% total body surface area burned, underwent an oral glucose tole

94 tcomes was lower, at approximately 40% total body surface area burned.

95 le organ failure was approximately 60% total body surface area burned.

96 er than 18 years or with more than 20% total body surface area burns (TBSA) burns were excluded.

97 nts (>/=16 years old) with 20% or more total body surface area burns recruited from 6 US burn centers

98 hours after injury, and more than 20% total body surface area burns requiring at least one surgical

99 pediatric patients with more than 30% total body surface area burns were randomized to control (n =

100 escribe a 22-year-old soldier with 19% total body surface area burns, polytrauma, and sequence- and c

101 was admitted to the burn unit with 50% total body surface area burns.

102 d mild, moderate, or severe disease based on body surface area criteria.

103 n Renal Disease formula result multiplied by body surface area divided by 1.73 m(2)) and the presence

104 ose of 0.75 (adjusted to 0.5 to 1.0) g/m2 of body surface area every 4 weeks for 6 months.

105 efore receiving an approximately 12.5% total body surface area full thickness burn.

106 o monitor accurately and easily the affected body surface area in a standardized way.

107 ty as objectively determined by the affected body surface area in both unadjusted and adjusted analys

108 rdial infarction (1.24 [1.08-1.42]), and low body surface area in men (1.22 [1.14-1.30]).

109 twice daily) or dacarbazine (1000 mg/m(2) of body surface area intravenously every 3 weeks).

110 moderate-to-severe chronic plaque psoriasis (body surface area involvement >/=10%, Physician's Global

111 ab, P = .005; and AHA, P = .006), extensive body surface area involvement (ssDNA ab, P = .01; and AN

112 ic records of patients with either SJS (<30% body surface area involvement) or TEN (> = 30% involveme

113 and 1242 women) aged 23.1+/-5.7 years, with body surface area of 1.9+/-0.2 m(2) and 8.9+/-4.9 years

114 57.1 and 53.6 years, respectively, P<0.0001; body surface area of 2.4 and 2.1 m(2), respectively, P<0

115 Fifty-four patients with burns to total body surface area of greater than or equal to 15%, intub

116 001) even after adjustment for their smaller body surface area or aortic annular area (both P<0.0001)

117 ricular indexed end-diastolic volume >125 mL/body surface area raised to the 1.3 power was associated

118 ce: Standard dosing of chemotherapy based on body surface area results in marked interpatient variati

119 Body surface area seems to be appropriate for indexation

120 nt confirmed and then subjected to 30% total body surface area steam burn injury.

121 The animals were exposed to 40% total body surface area third degree skin flame burn and 48 br

122 18 of these 92 products, a minimum weight or body surface area threshold is recommended for adolescen

123 Renal blood flow indexed to body surface area was 244 mL/min/m2 (range 165-662) in s

124 The total body surface area was 33% (22%-52%).

125 METHODS AND LA volume indexed to body surface area was measured by cardiovascular magneti

126 h age, height, and weight, normalization for body surface area was most efficient in removing the eff

127 terquartile range) age, body mass index, and body surface area were 68 (57-77) years, 28 (24-34) kg/m

128 he Psoriasis Area and Severity Index and the body surface area were assessed at baseline and at treat

129 ney morphological characteristics indexed to body surface area were associated inversely and independ

130 perative computed tomographic scans and (ii) body surface area were available entered the study.

131 Dimensions corrected by body surface area were higher in men than in women at th

132 3DE LA volumes indexed by body surface area were similar in men and women and incr

133 Age and body surface area were similar in the 4 valve morphology

134 Age, left ventricular mass, and body surface area were the main predictors of aortic dim

135 of LAV is currently performed by indexing to body surface area(1) (BSA(1)).

136 sed LV end-diastolic volume [EDV] indexed to body surface area) at baseline were excluded.

137 s in absolute and adjusted GS (corrected for body surface area) between 1 and 12 months after transpl

138 and efficacy of 32 doses of BTZ (1.3 mg/m of body surface area) in 10 highly sensitized kidney transp

139 r >/=upper 90th percentile for age, sex, and body surface area) or not enlarged; the hazard of an adv

140 n [AUC 5 or 6] and paclitaxel 175 mg/m(2) of body surface area) or the same chemotherapy regimen plus

141 ormulas (Lin or Vauthey using body weight or body surface area) rather than Urata's.

142 sed cardiac index (cardiac output divided by body surface area) to incident all-cause dementia and Al

143 the eTLV (calculated as -794.41 + 1267.28 x body surface area) using volumetric data (cm) and clinic

144 edian age 40 years, median burn size 6.0% of body surface area), 71% were men and 76% were White.

145 ce (n=121) of methotrexate (40-60 mg/m(2) of body surface area), docetaxel (30-40 mg/m(2)), or cetuxi

146 n 63 patients with major burns (>/=15% total body surface area).

147 rations as patients with larger burns (total body surface area, >/= 30%).

148 Magna/Magna Ease valves were smaller (median body surface area, 1.42 versus 1.93 m(2); P=0.002) and y

149 olume (left ventricular end-diastolic volume/body surface area, 104+/-13 and 69+/-18 mL/m(2); P<0.001

150 .001; right ventricular end-diastolic volume/body surface area, 110+/-22 and 66+/-16 mL/m(2); P<0.001

151 7 burn patients (mean age, 26.9 years; total body surface area, 16.1%) received 415 laser sessions (2

152 (SD) athlete height was 200.2 (8.8) cm; mean body surface area, 2.38 (0.19) m2.

153 Patients with lower burn severity (total body surface area, 20-30%) express similar metabolic alt

154 /-10 g/m(2); P<0.001; right ventricular mass/body surface area, 36+/-7 and 24+/-5 g/m(2); P<0.001) an

155 ight ventricular mass (left ventricular mass/body surface area, 96+/-13 and 62+/-10 g/m(2); P<0.001;

156 Total body surface area, age, and inhalation injury had signif

157 ndence after TP-IAT: (1) male sex, (2) lower body surface area, and (3) higher total IEQ per kilogram

158 hysiology and Chronic Health Evaluation III, body surface area, and age, sarcopenia index was indepen

159 re independent of age when dose is scaled to body surface area, and ESA resistance is associated with

160 sociations of age, body length, body weight, body surface area, and heart rate on PAAT were investiga

161 Age, sex, body surface area, and high-level endurance training wer

162 sions, parameters of body size (body weight, body surface area, and organ circumference) and gestatio

163 mass and function after controlling for age, body surface area, and sex.

164 malizing to body weight, lean body mass, and body surface area, and simplified measurements were comp

165 tients, including 1476 with burns >20% total body surface area, by presence of AKI.

166 l ventilation had a larger baseline detached body surface area, higher Logistic Organ Dysfunction sco

167 or primary outcomes: LV end-diastolic volume/body surface area, LV ejection fraction, LV end-diastoli

168 adius/wall thickness; LV end-systolic volume/body surface area, LV longitudinal strain rate, and LV e

169 agnetic resonance measures for age, sex, and body surface area, particularly given the changing demog

170 Corrected for age, sex, and body surface area, right ventricular end-systolic volume

171 of stroke between 11 and 365 days were small body surface area, severe aortic calcification, and fall

172 After adjusting for age, race, body surface area, systolic blood pressure, history of h

173 45 mm, lowered toward 40 in females with low body surface area, TGFBR2 mutation, and severe extra-aor

174 n multivariate regression analyses including body surface area, the 3 different MVA methods, and dPme

175 rn and smoke inhalation injury (40% of total body surface area, third-degree flame burn; 4 x 12 breat

176 Propensity matching based on age, sex, body surface area, total fluoroscopy time, and total acq

177 e, 9-40 years) and were indexed according to body surface area, with internal validation (R(2) = 0.84

178 ant trend, independent of age, toward larger body surface area-indexed ascending aortic diameters wit

179 and (3) the echocardiographically measured, body surface area-indexed, effective orifice area (EOAi

180 pression, particularly in those with smaller body surface area.

181 l vitiligo that involved 15% to 50% of total body surface area.

182 gen, panel reactive antibody >10%, and lower body surface area.

183 5) in end-systolic volume indexed (ESVi) to body surface area.

184 Volumetric measurements were indexed for body surface area.

185 her the hemodynamic measures were indexed to body surface area.

186 njection of 740 MBq (20 mCi) per 1.7 m(2) of body surface area.

187 n the basis of correlation existing with the body surface area.

188 id not correlate with age when normalized to body surface area.

189 rsal scald burn injury covering 30% of total body surface area.

190 evaluated with cardiac MRI and normalized to body surface area.

191 t of weight per moisturizer used for a given body surface area.

192 emales before but not after normalization to body surface area.

193 iligo involves an estimation of the affected body surface area.

194 y inverted after indexation of RV volumes to body surface area.

195 gnosed AD involving at least 5% of the total body surface area.

196 jected to a full-thickness burn of 30% total body surface area.

197 enting with marked systemic features and low body surface area.

198 dmitted with burns covering 52% of his total body surface area.

199 ved intravenous infusion of IdU (200 mg/m(2) body surface area; maximum dose, 400 mg) over a 30-minut

200 39 versus 112+/-33 mL/BSA(1.3), where BSA is body surface area; P=0.02).

201 related with the degree of RVH (RV thickness/body surface area; r(2)=0.838 and r(2)=0.818, respective

202 -weekly cycles of paclitaxel [175 mg/m(2) of body surface area] and carboplatin [area under the curve

203 r were divided into two cohorts according to body-surface area (cohort 1, <0.7 m(2); cohort 2, 0.7 to

204 imum aortic-root-diameter z score indexed to body-surface area (hereafter, aortic-root z score) over

205 ne dose of 4.3 g or more per square meter of body-surface area (which has been associated with premat

206 rapy at a dose of 375 mg per square meter of body-surface area administered every 2 months for 3 year

207 mpared rituximab (375 mg per square meter of body-surface area administered once a week for 4 weeks)

208 evere disease) and with 10% or more of their body-surface area affected by psoriasis to receive broda

209 30.0 to 89.9 ml per minute per 1.73 m(2) of body-surface area and then randomly assigned them to rec

210 ne (at a dose of 1000 mg per square meter of body-surface area every 3 weeks and nivolumab-matched pl

211 axel (at a dose of 75 mg per square meter of body-surface area every 3 weeks for six cycles) or ADT a

212 usly at a dose of 175 mg per square meter of body-surface area every 3 weeks, plus carboplatin (dose

213 axel, at a dose of 75 mg per square meter of body-surface area every 3 weeks.

214 taxel at a dose of 75 mg per square meter of body-surface area every 3 weeks.

215 [eGFR] of <5 ml per minute per 1.73 m(2) of body-surface area from baseline) and a decrease in the e

216 VESVI was 41.2+/-20.0 ml per square meter of body-surface area in the CABG-alone group and 43.2+/-20.

217 ients was 46.1+/-22.4 ml per square meter of body-surface area in the CABG-alone group and 49.6+/-31.

218 ere 68 and 70 ml per minute per 1.73 m(2) of body-surface area in the development and validation data

219 ients was 54.6+/-25.0 ml per square meter of body-surface area in the repair group and 60.7+/-31.5 ml

220 ore baseline (randomisation), 10% or greater body-surface area involvement at both screening and base

221 at a dose of 20 to 30 mg per square meter of body-surface area on a continuous dosing schedule (in 28

222 ing of docetaxel (100 mg per square meter of body-surface area on day 1), docetaxel (75 mg per square

223 omib at a dose of 1.3 mg per square meter of body-surface area on days 1, 4, 8, and 11).

224 ion of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg pe

225 R of 25 to 65 ml per minute per 1.73 m(2) of body-surface area or 56 to 65 years of age with an estim

226 tered at a dose of 20 mg per square meter of body-surface area per day for 10 consecutive days in mon

227 of fluorouracil (500 mg per square meter of body-surface area per day) during fractions 1 to 5 and 1

228 alan at a dose of 200 mg per square meter of body-surface area plus autologous stem-cell transplantat

229 f at least 30 ml per minute per 1.73 m(2) of body-surface area to receive either empagliflozin (at a

230 less than 60 ml per minute per 1.73 m(2) of body-surface area was higher with the cystatin C-based e

231 ease in the aortic-root diameter relative to body-surface area with either treatment.

232 VESVI was 52.6+/-27.7 ml per square meter of body-surface area with mitral-valve repair and 60.6+/-39

233 erapy (melphalan, 140 mg per square meter of body-surface area) and autologous stem-cell transplantat

234 ceive bortezomib (1.3 mg per square meter of body-surface area) and dexamethasone (20 mg) alone (cont

235 o nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per

236 e) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiothera

237 ] of 20 to 45 ml per minute per 1.73 m(2) of body-surface area) in a 1:1:1:1 ratio to receive placebo

238 ving cisplatin (>/=70 mg per square meter of body-surface area) or cyclophosphamide-doxorubicin.

239 ither pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter)

240 ous dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square mete

241 R], 15 to <30 ml per minute per 1.73 m(2) of body-surface area) to bardoxolone methyl, at a daily dos

242 ate [GFR] >60 ml per minute per 1.73 m(2) of body-surface area) to either a standard blood-pressure t

243 FR], 25 to 60 ml per minute per 1.73 m(2) of body-surface area) to receive an ACE inhibitor (lisinopr

244 ase (eGFR <60 ml per minute per 1.73 m(2) of body-surface area) were analyzed with the use of linear

245 starting dose of everolimus depended on age, body-surface area, and concomitant use of cytochrome 3A4

246 axel at a dose of 175 mg per square meter of body-surface area, plus carboplatin at an area under the

247 latin at a dose of 50 mg per square meter of body-surface area, plus paclitaxel at a dose of 135 or 1

248 -1.51+/-1.33 ml per minute per 1.73 m(2) of body-surface area, respectively.

249 Cluster 1 had high SASSAD scores and body surface areas with the highest levels of pulmonary

250 al Clearance to Eradicate MRSA]) showed that body surface decolonisation reduced all-pathogen bloodst

251 ized in three parallel maps representing the body surface determine responses to second-order electro

252 On the body surface, different ectodermal organs exhibit distin

253 distribution of bacterial communities on the body surface during development of the model organism Hy

254 ial activation maps were generated from >250 body surface ECGs using heart-torso geometry obtained fr

255 e of noninvasive imaging techniques based on body surface electrocardiographic mapping to elucidate t

256 iatrial geometry relative to an array of 252 body surface electrodes was obtained from a noncontrast

257 The ECM consisted of recording body surface electrograms from a 252-electrode-vest plac

258 Human body-surface epithelia coexist in close association with

259 Many body surfaces harbor organ-specific gammadelta T cell co

260 ers of microorganisms that inhabit mammalian body surfaces have a highly coevolved relationship with

261 hance not only the reflectivity of the ant's body surface in the visible and near-infrared range of t

262 gestation, but during and after birth, every body surface, including the skin, mouth, and gut, become

263 In clinical data, body-surface-indexed EDV and ESV (mL/m(2)) were higher f

264 6 (38% [95% CI, 27 to 51%]) had GBS on their body surfaces, indicating vertical transmission.

265 Power spectra of surface leads and the body surface location of the highest DF site were compar

266 Body surface mapping showed that the area with ST-segmen

267 nts, endocardial, epicardial RV (CARTO), and body surface mapping was performed.

268 Patients wore a 252-electrode vest for body surface mapping.

269 in Europeans, whereas it arises in internal body surfaces (mucosal sites) and on the hands and feet

270 FAEEs), which are produced abundantly on the body surface of the vector beetle specifically during th

271 al or tactile stimuli presented on their own body surface, or pictures of hands and feet within arm's

272 mation about spatio-temporal dynamics of the body surface potential (BSP) during atrial excitation.

273 able variance between simulated and measured body surface potential distributions.

274 Differences between the body surface potential extrema predicted with homogeneou

275 and ectopic activation, together with pseudo-body surface potential map ECGs in 2 of them.

276 Calculation of the inverse solution from body surface potential mapping (sometimes known as ECG i

277 Bipolar EGMs and body surface potential mapping do require HDF filtering

278 In body surface potential mapping maps, HDF filtering incre

279 ttern characterization in electrogram (EGM), body surface potential mapping, and electrocardiographic

280 METHODS AND EGM, body surface potential mapping, and electrocardiographic

281 atheter mapping and ablation of VT, 120-lead body surface potential mappings were obtained during imp

282 situ pig hearts, estimating activation from body surface potential maps during sinus rhythm and loca

283 From 4 other anesthetized pigs, 64-lead body surface potential maps were recorded during sinus r

284 h endocardial and epicardial activation from body surface potential maps.

285 The relationship between epicardial and body surface potentials defines the forward problem of e

286 Body surface potentials were simulated from epicardial r

287 ) forward models were compared with measured body surface potentials.

288 picardial potentials are computed from known body surface potentials.

289 computation of epicardial electrograms from body surface potentials.

290 Spectral analysis of body surface recordings during AF allows a noninvasive c

291 In 14 patients with a history of AF, 67-lead body surface recordings were simultaneously registered w

292 pic herpesviruses from the nervous system to body surfaces, referred to as anterograde axonal traffic

293 ildren with burns exceeding 30% of the total body surface, requiring at least 1 surgical procedure we

294 Although body surface scanning with a standard Geiger counter was

295 numbers of observed viral genotypes on many body surfaces studied, including the oral, gastrointesti

296 nismal functions are size-dependent whenever body surfaces supply body volumes.

297 At our body surface, the epidermis absorbs UV radiation.

298 ish grow and neuromasts proliferate over the body surface, the number of afferent neurons increases l

299 of tissue resident memory (TRM) cells at the body surfaces to provide a front line defence against in

300 response against infections reencountered at body surfaces, where they accelerate pathogen clearance.